P2D, INC.

Basic Information

10101 Alliance Rd
CINCINNATI, OH, 45242-4739

Company Profile

n/a

Additional Details

Field Value
DUNS: 182472162
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. PancreasCHIP- A diagnostic tool for Inheritable Pancreatic Disease

    Amount: $266,046.00

    DESCRIPTION provided by applicant Pancreatitis is a painful condition that may become recurrent or chronic in genetically susceptible individuals Patients with pancreatitis suffer multiple hospita ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.

    Amount: $745,321.00

    DESCRIPTION provided by applicant The goal of this proposal is to develop tumor necrosis factor a TNFa inhibiting compounds as neuroprotectant drugs for treating Alzheimerandapos s disease AD ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Novel Alzheimer's Disease Drug Treatment

    Amount: $224,905.00

    DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (A ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML

    Amount: $224,629.00

    DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the d ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat

    Amount: $366,718.00

    Abstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunod ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Rho GTPase inhibitors for refrigerated platelet storage

    Amount: $224,700.00

    ABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24 C aft ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. LIVERCHIP- A diagnostic tool for genetic liver diseases

    Amount: $1,178,516.00

    DESCRIPTION provided by applicant Genetic mutations are known to cause acute and chronic liver diseases and are being increasingly recognized as drivers of phenotype severity As a group these di ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  8. Coronary Post-Dilatation Catheter

    Amount: $395,476.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Cu ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. Pharmacological rejuvenation of aged hematopoietic stem cells.

    Amount: $361,403.00

    DESCRIPTION (provided by applicant): The demographic development in most Western countries predicts that age-associated diseases and their prevention will become an important social, economic and med ...

    SBIR Phase I 2012 Department of Health and Human Services
  10. A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.

    Amount: $390,959.00

    DESCRIPTION (provided by applicant): The goal of this application is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government